Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia

American Journal of Clinical Pathology

Volumn 133, Issue 1, 2010, Pages 70-74

  Chang, Hong ^a,b   Jiang, Allan M ^a,b   Qi, Connie X Y ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic lymphocytic leukemia; FISH; Fluorescence in situ hybridization; Immunohistochemistry; p53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC RISK; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRISOMY 12;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL NUCLEUS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HETEROZYGOTE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73949120475     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPEPX1C7HHFELK     Document Type: Article

References (21)

1. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1987;342:705-708.
2. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991;6:1699-1703.
3. Lepelley P, Preudhomme C, Vanrumbeke M, et al. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia. 1994;8:1342-1349.
4. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer. 2001;1:68-76.
5. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in humans. Cell. 2006;127:1323-1324.
6. Villuendas R, Piris MA, Algara P, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood. 1993;82:3151-3156.
7. Cesarman E, Inghirami G, Chadburn A, et al. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol. 1993;143:845-856.
8. Kocialkowski S, Pezzella F, Morrison H, et al. Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol. 1995;89:55-60.
9. Maestro R, Gloghini A, Doglioni C, et al. Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood. 1997;89:2523-2528.
10. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
11. Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322-3329.
12. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342-4349.
13. Klobusická M, Kusenda J, Babusíková O. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Neoplasma. 2002;49:387-393.
14. Giles FJ, Bekele BN, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003;121:578-585.
15. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
16. WHO Classification of Tumours; vol 2.
17. Chang H, Wechalekar A, Li L, et al. Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. Cancer Genet Cytogenet. 2004;148:44-48.
18. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J. 2004;5:47-54.
19. Lens D, Dyer MJS, Garcia-Marco JM, et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol. 1997;99:848-857.
20. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-ARF: progress and puzzles. Curr Opin Genet Dev. 2002;13:77-83.
21. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001-1008.